The global atrial fibrillation drugs market size was valued at USD 24.59 billion in 2024 and is projected to reach from USD ...

A 240-year-old drug called digoxin could save the National Health Service (NHS) at least £100 million each year when treating ...

Recent research shows the incredible success of radiofrequency ablation in treating AFib, offering renewed hope for patients.

The following is a summary of “Cost-effectiveness of digoxin versus beta blockers in permanent atrial fibrillation: the Rate Control Therapy Evaluation in Permanent Atrial Fibrillation (RATE-AF) ...

Discover how abelacimab reduces bleeding risks in AFib patients by effectively lowering free factor XI levels.

Researchers have found in a new research that among patients with atrial fibrillation who are at moderate-to-high risk for ...

Patients with atrial fibrillation are typically prescribed an anticoagulant, or blood thinner, to reduce the risk of stroke, but many may discontinue them or never receive a prescription due to ...

A new treatment at Unity Point Health is offering promising results for those with irregular heartbeats, otherwise known as ...

Researchers evaluated a drug that represents a new class of anticoagulants known as Factor XI inhibitors for treating patients with atrial fibrillation as part of the AZALEA-TIMI 71 Study. The trial ...

our research suggests that targeting NOX2 could offer a new treatment strategy to prevent or reduce the severity of irregular ...